ZBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Zimmer Biomet Holdings Inc (ZBH) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock's technical indicators suggest overbought conditions, and the options data reflects a bearish sentiment. While the company has shown revenue growth, its net income and EPS have significantly declined, raising concerns about profitability. Analyst ratings are mixed, with some highlighting execution issues. Given the lack of strong positive catalysts and the current market sentiment, holding off on buying ZBH is advisable for now.
The MACD is positive but contracting, indicating a potential slowdown in upward momentum. RSI is at 89.73, signaling overbought conditions. The stock is trading near resistance levels (R1: 100.837, R2: 102.473), suggesting limited upside potential in the short term.
The company declared a consistent quarterly dividend of $0.24 per share, reflecting stability in shareholder returns. Revenue increased by 10.90% YoY in Q4 2025.
Net income and EPS dropped significantly YoY in Q4 2025, down -41.84% and -41.67%, respectively. Gross margin also declined by -10.19%. Analyst ratings are mixed, with some highlighting execution issues and inconsistent growth. The stock has a 70% chance of declining in the short term based on candlestick pattern analysis.
In Q4 2025, revenue increased to $2.24 billion, up 10.90% YoY. However, net income dropped to $139.3 million (-41.84% YoY), and EPS fell to $0.7 (-41.67% YoY). Gross margin also declined to 56.77% (-10.19% YoY), indicating profitability challenges.
Analyst ratings are mixed. Some analysts have downgraded the stock due to inconsistent growth and execution issues, while others see potential for improvement. Price targets range from $86 to $120, with a median target near the current price, suggesting limited upside.
